Overexpression of the RD RNA binding protein in hepatitis C virus-related hepatocellular carcinoma

Iida,Michihisa; Iizuka,Norio; Tsunedomi,Ryouichi; Tsutsui,Masahiro; Yoshida,Shin; Maeda,Yoshinari; Tokuhisa,Yoshihiro; Sakamoto,Kazuhiko; Yoshimura,Kiyoshi; Tamesa,Takao; Oka,Masaaki

doi:10.3892/or.2012.1821

Overexpression of the RD RNA binding protein in hepatitis C virus-related hepatocellular carcinoma

Authors:
- Michihisa Iida
- Norio Iizuka
- Ryouichi Tsunedomi
- Masahiro Tsutsui
- Shin Yoshida
- Yoshinari Maeda
- Yoshihiro Tokuhisa
- Kazuhiko Sakamoto
- Kiyoshi Yoshimura
- Takao Tamesa
- Masaaki Oka
View Affiliations

Affiliations: Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan
Published online on: May 18, 2012 https://doi.org/10.3892/or.2012.1821
Pages: 728-734

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) often exhibits a poor prognosis due to metastatic spread caused by portal vein invasion (PVI). In the present study, we attempted to identify a novel therapeutic target related to PVI of HCC. Based on pooled genomic data, we identified RD RNA binding protein (RDBP), a member of the negative elongation factor (NELF) transcription elongation regulatory complex, to be preferentially overexpressed in HCC with PVI. We used quantitative reverse transcription polymerase chain reaction (RT-PCR) and immuno-histochemical analyses to investigate the relationship between RDBP mRNA and protein with metastatic potential in sample sets of hepatitis C virus (HCV)-related HCC and corresponding non-HCC liver tissues. We also used the small interfering RNA technique to examine the role of RDBP in invasion and proliferation of HCC cells in vitro. Our data showed that both mRNA and protein levels of RDBP were significantly higher in HCC compared to non-HCC liver tissue, and that these levels were also significantly higher in HCC with PVI compared to HCC without PVI. Multivariate analysis revealed that RDBP protein levels were an independent risk factor for early intrahepatic recurrence of HCC within 2 years of surgery. Knockdown of RDBP protein significantly inhibited the proliferation and invasion of cells in vitro. These data demonstrate that RDBP is related to the metastatic potential of HCC, suggesting a possible candidate for prevention of HCC cell metastasis.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Thorgeirsson SS and Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
3	Ohishi W, Kitamoto M, Aikata H, Kamada K, Kawakami Y, Ishihara H, Kamiyasu M, Nakanishi T, Tazuma S and Chayama K: Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol. 38:894–900. 2003. View Article : Google Scholar : PubMed/NCBI
4	Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y and Yamaoka Y: Report of the 16th follow-up survey of primary liver cancer. Hepatol Res. 32:163–172. 2005. View Article : Google Scholar : PubMed/NCBI
5	Thomas MB and Zhu AX: Hepatocellular carcinoma: the need for progress. J Clin Oncol. 23:2892–2899. 2005. View Article : Google Scholar : PubMed/NCBI
6	Shirabe K, Kanematsu T, Matsumata T, Adachi E, Akazawa K and Sugimachi K: Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology. 14:802–805. 1991. View Article : Google Scholar
7	Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, Hamada K, Nakayama H, Ishitsuka H, Miyamoto T, Hirabayashi A, Uchimura S and Hamamoto Y: Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 361:923–929. 2003. View Article : Google Scholar : PubMed/NCBI
8	Shirabe K, Wakiyama S, Gion T, Motomura K, Koyanagi T, Sakamoto S and Nagaie T: Clinicopathological risk factors linked to recurrence pattern after curative hepatic resection for hepatocellular carcinoma - results of 152 resected cases. Hepatogastroenterology. 54:2084–2087. 2007.
9	Iizuka N, Oka M, Yamada-Okabe H, Mori N, Tamesa T, Okada T, Takemoto N, Sakamoto K, Hamada K, Ishitsuka H, Miyamoto T, Uchimura S and Hamamoto Y: Self-organizing-map-based molecular signature representing the development of hepatocellular carcinoma. FEBS Lett. 579:1089–1100. 2005. View Article : Google Scholar : PubMed/NCBI
10	Surowy CS, Hoganson G, Gosink J, Strunk K and Spritz RA: The human RD protein is closely related to nuclear RNA-binding proteins and has been highly conserved. Gene. 90:299–302. 2007. View Article : Google Scholar : PubMed/NCBI
11	Cheng J, Macon KJ and Volanakis JE: cDNA cloning and characterization of the protein encoded by RD, a gene located in the class III region of the human major histocompatibility complex. Biochem J. 294:589–593. 1993.
12	Yamaguchi Y, Takagi T, Wada T, Yano K, Furuya A, Sugimoto S, Hasegawa J and Handa H: NELF, a multisubunit complex containing RD, cooperates with DSIF to repress RNA polymerase II elongation. Cell. 97:41–51. 1999. View Article : Google Scholar : PubMed/NCBI
13	Yamaguchi Y, Inukai N, Narita T, Wada T and Handa H: Evidence that negative elongation factor represses transcription elongation through binding to a DRB sensitivity-inducing factor/RNA polymerase II complex and RNA. Mol Cell Biol. 22:2918–2927. 2002. View Article : Google Scholar
14	Narita T, Yamaguchi Y, Yano K, Sugimoto S, Chanarat S, Wada T, Kim DK, Hasegawa J, Omori M, Inukai N, Endoh M, Yamada T and Handa H: Human transcription elongation factor NELF: identification of novel subunits and reconstitution of the functionally active complex. Mol Cell Biol. 23:1863–1873. 2003. View Article : Google Scholar : PubMed/NCBI
15	Sakon M, Umeshita K, Nagano H, Eguchi H, Kishimoto S, Miyamoto A, Ohshima S, Dono K, Nakamori S, Gotoh M and Monden M: Clinical significance of hepatic resection in hepatocellular carcinoma: analysis by diseasefree survival curves. Arch Surg. 135:1456–1459. 2003. View Article : Google Scholar : PubMed/NCBI
16	Tsunedomi R, Iizuka N, Tamesa T, Sakamoto K, Hamaguchi T, Somura H, Yamada M and Oka M: Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. Clin Cancer Res. 14:1025–1031. 2008. View Article : Google Scholar
17	Waxman S and Wurmbach E: De-regulation of common housekeeping genes in hepatocellular carcinoma. BMC Genomics. 8:2432007. View Article : Google Scholar : PubMed/NCBI
18	Cheng AL, Huang WG, Chen ZC, Peng F, Zhang PF, Li MY, Li F, Li JL, Li C, Yi H, Yi B and Xiao ZQ: Identification of novel nasopharyngeal carcinoma biomarkers by laser capture microdissection and proteomic analysis. Clin Cancer Res. 14:435–445. 2008. View Article : Google Scholar : PubMed/NCBI
19	Poon RT, Ng IO, Fan ST, Lai EC, Lo CM, Liu CL and Wong J: Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. J Clin Oncol. 19:3037–3044. 2001.PubMed/NCBI
20	Vauthey JN, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, Cleary KR and Nagorney DM: Simplified staging for hepatocellular carcinoma. J Clin Oncol. 20:1527–1536. 2002. View Article : Google Scholar : PubMed/NCBI
21	Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, van De Rijn M, Botstein D and Brown PO: Gene expression patterns in human liver cancers. Mol Biol Cell. 13:1929–1939. 2002. View Article : Google Scholar PubMed/NCBI
22	Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y and Nakamura Y: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61:2129–2137. 2001.
23	Tsunedomi R, Iizuka N, Yamada-Okabe H, Tamesa T, Okada T, Sakamoto K, Takashima M, Hamaguchi T, Miyamoto T, Uchimura S, Hamamoto Y, Yamada M and Oka M: Identification of ID2 associated with invasion of hepatitis C virus-related hepatocellular carcinoma by gene expression profile. Int J Oncol. 29:1445–1451. 2006.PubMed/NCBI
24	Tanaka S, Mogushi K, Yasen M, Noguchi N, Kudo A, Nakamura N, Ito K, Miki Y, Inazawa J, Tanaka H and Arii S: Gene-expression phenotypes for vascular invasiveness of hepatocellular carcinomas. Surgery. 147:405–414. 2009. View Article : Google Scholar : PubMed/NCBI
25	Iizuka N, Hamamoto Y, Tsunedomi R and Oka M: Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Sci. 99:659–665. 2008. View Article : Google Scholar : PubMed/NCBI
26	Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
27	Matoba K, Iizuka N, Gondo T, Ishihara T, Yamada-Okabe H, Tamesa T, Takemoto N, Hashimoto K, Sakamoto K, Miyamoto T, Uchimura S, Hamamoto Y and Oka M: Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer. 115:231–240. 2005. View Article : Google Scholar : PubMed/NCBI
28	Narita T, Yung TM, Yamamoto J, Tsuboi Y, Tanabe H, Tanaka K, Yamaguchi Y and Handa H: NELF interacts with CBC and participates in 3′ end processing of replication-dependent histone mRNAs. Mol Cell. 26:349–365. 2007.PubMed/NCBI
29	Sun J, Watkins G, Blair AL, Moskaluk C, Ghosh S, Jiang WG and Li R: Deregulation of cofactor of BRCA1 expression in breast cancer cells. J Cell Biochem. 103:1798–1807. 2008. View Article : Google Scholar : PubMed/NCBI
30	Zou W, Yang Y, Wu Y, Sun L, Chi Y, Wu W, Yun X, Xie J and Gu J: Negative role of trihydrophobin 1 in breast cancer growth and migration. Cancer Sci. 101:2156–2162. 2008. View Article : Google Scholar : PubMed/NCBI
31	Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
32	Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar